Patents by Inventor Govind Ragupathi

Govind Ragupathi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230219991
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 8, 2023
    Publication date: July 13, 2023
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20210283248
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: April 25, 2018
    Publication date: September 16, 2021
    Applicants: Adjuvance Technologies, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Philip LIVINGSTON, Govind RAGUPATHI, Jeffrey GARDNER, J Tyler MARTIN
  • Publication number: 20210236630
    Abstract: The present disclosure provides methods for enhancing the immunogenicity of a poorly immunogenic antigen-specific vaccine as well as methods for promoting diversification of the gut microbiome in a subject in need thereof comprising administering to the subject an effective amount of a beta-glucan extract derived from yeast. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 5, 2021
    Inventors: Nai-Kong CHEUNG, Shakeel MODAK, Govind RAGUPATHI
  • Patent number: 10906926
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER
    Inventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
  • Publication number: 20210002316
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: January 7, 2021
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20200239509
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 30, 2020
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Publication number: 20190048073
    Abstract: The present invention provides for anti-GD3 antibodies, and ADCs and methods for preparing and using the same.
    Type: Application
    Filed: July 19, 2018
    Publication date: February 14, 2019
    Inventors: Faical Miyara, Dhanvanthri S Deevi, Lioudmila Tchistiakov, Michelle Mader, Yijie Gao, Paul Chapman, Govind Ragupathi
  • Publication number: 20180327436
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 15, 2018
    Applicant: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Patent number: 9598466
    Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: March 21, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Jianglong Zhu, Dongjoo Lee, Philip Livingston, Govind Ragupathi
  • Patent number: 9493580
    Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 15, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, David R. Spriggs
  • Publication number: 20150086585
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: David GIN, Michaelle ADAMS, Kai DENG, Nicholas PERL, Annie WON, Philip LIVINGSTON, Govind RAGUPATHI
  • Publication number: 20150023954
    Abstract: Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mAb”) against cancer antigens or cancer antigens with low tumor cell density. While detectable levels of passively administered or vaccine-induced mAb against some antigens are able to delay or prevent tumor growth, low levels of mAb induce sublytic levels of complement activation and accelerate tumor growth. This complement-mediated accelerated tumor growth initiated by low mAb levels results in activation of the PI3K/AKT survival pathway. Methodologies and technologies relating to administration of PI3K inhibitors to overcome low dose mAb-initiated, complement-mediated PI3K activation and accelerated tumor growth are disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 22, 2015
    Inventors: Xiaohong Wu, Wolfgang W. Scholz, Govind Ragupathi, Philip O. Livingston
  • Patent number: 8889842
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 18, 2014
    Assignee: Sloan-Kettering Insititute for Cancer Research
    Inventors: David Y. Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Publication number: 20130095173
    Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 18, 2013
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, Karthik Iyer, Guangbin Yang
  • Publication number: 20130011421
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Patent number: 8283456
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 9, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Publication number: 20110300177
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: April 8, 2009
    Publication date: December 8, 2011
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Publication number: 20110229510
    Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Application
    Filed: July 13, 2009
    Publication date: September 22, 2011
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Jianglong Zhu, Qian Wan, Insik Jeon, Woohan Kim, Pavel Nagorny, Dongjoo Lee, Philip Livingston, Govind Ragupathi
  • Publication number: 20080241195
    Abstract: This invention provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of : a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine.
    Type: Application
    Filed: October 6, 2006
    Publication date: October 2, 2008
    Inventors: Philip O. Livingston, Govind Ragupathi